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Abstract Peptide receptor radionuclide therapy (PRRT)
has been shown to be an effective treatment for neuroen-
docrine tumors (NETs) if curative surgery is not an option.
A majority of NETs abundantly express somatostatin
receptors. Consequently, following administration of
somatostatin (SST) analogs labeled with c-emitting radio-
nuclides, these tumors can be imaged for diagnosis, staging
or follow-up purposes. Furthermore, when b-emitting ra-
dionuclides are used, radiolabeled peptides (radiopeptides)
can also be used for the treatment for NET patients. Even
though excellent results have been achieved with PRRT,
complete responses are still rare, which means that there is
room for improvement. In this review, we highlight some
of the directions currently under investigation in pilot
clinical studies or in preclinical development to achieve
this goal. Although randomized clinical trials are still
lacking, early studies have shown that tumor response
might be improved by application of other radionuclides,
such as a-emitters or radionuclide combinations, or by
adjustment of radiopeptide administration routes. Individ-
ualized dosimetry and better insight into tumor and normal
organ radiation doses may allow adjustment of the amount
of administered activity per cycle or the number of treat-
ment cycles, resulting in more personalized treatment
schedules. Other options include the application of novel
(radiolabeled) SST analogs with improved tumor uptake
and radionuclide retention time, or a combination of PRRT
with other systemic therapies, such as chemotherapy or
treatment with radio sensitizers. Though promising direc-
tions appear to bring improvements of PRRT within reach,
additional research (including randomized clinical trials) is
needed to achieve such improvements.
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Introduction
Neuroendocrine tumors (NETs) are well-differentiated
tumors derived from diffuse neuroendocrine cells in the
lung, gut or pancreas. NETs are rare, having an incidence
of 2–5 per 100,000 inhabitants [1–3]; their prevalence,
however, is much higher on account of the relatively slow
progression rate of the disease [3]. In general, NETs are
diagnosed at a relatively late stage, with metastatic spread
present at the time of diagnosis in the majority of patients
[3]. Often, therefore, curative surgery is no longer an
option. Since chemotherapy and external beam therapy are
incapable of treating distant metastases, in most cases these
therapeutic options are of limited value [4]. Peptide
receptor radionuclide therapy (PRRT) using radiolabeled
somatostatin (SST) analogs has proven to be an effective
therapeutic option for NET patients with metastasized
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disease, as it allows targeted delivery of therapeutic ra-
dionuclides to tumor cells [5, 6]. Despite the fact that high
tumor response rates have been reported after treatment
with177Lu-DOTA,Tyr3-octreotate (DOTA = 1,4,7,10-tet-
raazacyclododecane-1,4,7,10-tetra-acidic acid) (177Lu-
DOTATATE) [7] and 90Y-DOTA,Tyr3-octreotide
(90Y-DOTATOC) [8], complete responses are still rare,
indicating that there is room for improvement of PRRT.
The aim of this review is to describe directions that may
lead to improvement of imaging and especially treatment
of NETs with radiolabeled SST analogs.
SST is a biologically active neuropeptide secreted by the
hypothalamus. It acts by binding to G-protein-coupled
somatostatin receptors (SSTRs) expressed in different
organs in the body, such as the gastrointestinal tract and the
pancreas [9]. SST inhibits the secretion of a wide range of
hormones. Besides this normal organ expression, SSTRs
are (over)expressed by certain malignant tissues, in par-
ticular most NETs [10]. SSTRs consist of five G-protein-
coupled receptors, subtypes SSTR1–SSTR5 [11], of which
SSTR2, in particular, is (over)expressed by NETs [12]. The
abundant expression of SSTRs by the majority of NETs
enables their visualization in patients. This is achieved,
using nuclear imaging techniques, by receptor targeting
with radiolabeled SST peptide analogs such as octreotide
(D-Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr(ol)) or Tyr3-
octreotate (D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Thr)
[13, 14]. These stabilized eight-amino acid compounds are
derived from native SSTs which consist of 14 or 28 amino
acids [15]. Unlabeled SST analogs like long-acting release
octreotide (octreotide LAR) are currently applied as initial
treatment for patients with metastatic midgut NETs [16].
Octreotide LAR has been shown to have a positive influ-
ence on clinical symptoms as well as some tumor-stabi-
lizing effects, leading to a lengthening of time to
progression compared with placebo [16].
Functional imaging using SPECT or PET imaging with
the radiolabeled SST analogs 111Indium-DTPA (diethyle-
netriaminepentaacetic acid) -octreotide (111In-octreotide,
or Octreoscan; Mallinckrodt, Petten, the Netherlands)
[13], 68Ga-DOTA-Tyr3-octreotide (68Ga-DOTATOC),
68Ga -DOTA, 1-Nal3-octreotide (68Ga -DOTANOC),
68Ga-DOTA-Tyr3-octreotate (68Ga-DOTATATE) [17],
99mTc-EDDA/HYNIC-octreotate [18], or 99mTc-EDDA/
HYNIC-octreotide [19] is being widely applied in clinical
practice for diagnosis, staging and monitoring of NETs.
111In-octreotide is currently the only registered imaging
tracer [20]. Over the last few years, however, SST analogs
radiolabeled with the positron emitter 68Ga have been
increasingly used for PET imaging. Compared with SPECT
using 111In-labeled analogs, PET using 68Ga-labeled ana-
logs resulted in a higher spatial resolution, better tissue
contrast, and a higher sensitivity for detection of
metastases. Several studies have shown PET with 68Ga-
labeled SST analogs to be superior to SPECT performed
using 111In-labeled STT analogs [21, 22]. In addition, as
68Ga is generator produced [23], it allows for in-house
labeling and applications of 68Ga in nuclear medicine
departments which do not have access to a cyclotron.
Following the successful applications of 111In-octreotide
for imaging of NETs, the next logical step was to apply this
radionuclide, not only emitting c radiation but also thera-
peutic Auger and conversion electrons, at high activities for
PRRT of metastasized disease as well [24, 25]. Although
treatment with 111In-octreotide often resulted in symptom
relief in patients with metastasized NETs, objective tumor
responses were rare, especially in patients with advanced
disease and in those with large tumors [8, 24, 25]. Appli-
cation of 177Lu-DOTATATE and 90Y-DOTATOC, on the
other hand, resulted in impressive therapeutic effects [8,
26–29]. Since 177Lu also emits c rays, 177Lu-labeled pep-
tides can be used for treatment as well as for dosimetry and
monitoring of tumor response. The first clinical phase III
study to evaluate safety and tolerability of 177Lu-DOTA-
TATE and compare therapeutic responses after 177Lu-
DOTATATE with those after treatment with a high dose of
the unlabeled SST analog octreotide LAR is currently
running in several countries (http://clinicaltrials.gov/ct2/
show/NCT01578239?term=NCT01578239&rank=1).
As mentioned above, PRRT has been shown to be a
promising treatment option for NET patients. Several
excellent reviews have recently described the current status of
PRRT in great detail [30, 31]. Within the space constraints of
this article we cannot cover every aspect of this exciting field,
but we nevertheless aim to help readers appreciate the
available options for increasing tumor response after PRRT
and to point out some of the latest developments. On the basis
of published research, we discuss, below, five ways of
increasing the therapeutic effects of PRRT:
1. Recently developed STT analogs acting as receptor
antagonists seem to be a highly promising alternative
to the receptor agonists currently applied in clinical
practice, as several newly developed SSTR antagonists
have shown increased tumor uptake compared to
STTR agonists [32–34], leading to higher tumor
radiation doses. We report on recently achieved results
in different tumor models, and discuss the possible
mechanisms behind these results and the translation of
preclinical studies into the clinic.
2. The use of combinations of selected radionuclides for
labeling SST analogs might improve tumor responses.
As dose rate, emitted energies and linear energy transfer
(LET) are specific for every radionuclide, the radionuc-
lides with the most appropriate characteristics could be
combined to obtain optimal effects. Since metastases
56 Clin Transl Imaging (2014) 2:55–66
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range in size from small to large tumor masses, we report
on the published advantages of combined applications of
177Lu and 90Y for the treatment of small and large
metastases, respectively. Furthermore, we highlight the
use of the several most promising a-emitters, which are
currently being applied in PRRT in experimental studies.
3. Increased uptake of radionuclides in liver metastases has
been achieved after **intra-arterial (i.a.) administration
(into the hepatic artery) as opposed to intravenous (i.v.)
injection. Below, we describe preclinical and clinical
results achieved after i.a. injection and focus on points of
interest concerning this new therapeutic approach.
4. Dosimetry during PRRT is of great interest and
application of patient-specific dosimetry might allow
safe administration of additional treatment cycles to
possibly increase tumor response to PRRT.
5. Finally, the combination of PRRT with other therapies
might increase the effectiveness of treatment for NET
patients. From this perspective, a new application of
PRRT is to use it in a neo-adjuvant or adjuvant setting,
to allow curative surgery after tumor mass reduction
by PRRT or to prevent the development of metastases
after spread of tumor cells during surgery. We also
focus on increased therapeutic responses after com-
bined PRRT and chemotherapy. Promising combina-
tions of PRRT and chemotherapeutics are under
preclinical as well as clinical evaluation.
Recently developed somatostatin analogs
The SST analogs currently most widely used in the clinical
setting include 111In- octreotide (Octreoscan) and 68Ga-
DOTATOC/DOTATATE/DOTANOC for imaging, and
177Lu-DOTATATE and 90Y-DOTATOC for therapy. Sev-
eral novel, radiolabeled SST analogs are currently under
preclinical and clinical evaluation, as recently reviewed by
Fani et al. [30]. Of particular interest are the pansoma-
tostatin analogs, targeting multiple SSTR subtypes [35],
and SSTR antagonists. As pansomatostatin analogs like
DOTA-lanreotide target more SSTR subtypes than, e.g.,
DOTATOC, the use of DOTALAN can be considered in
patients lacking tumor uptake of DOTATOC [36].
Very promising results have been reported with regard to
the application of SSTR antagonists. Until recently it was
generally assumed that receptor-targeting ligands should act
as receptor agonists to promote efficient internalization of
receptor ligand complexes into tumor cells, causing accu-
mulation and long retention of radionuclides within tumors
[37]. However, recent studies have shown significantly
increased tumor targeting with SSTR antagonists, despite
minimal or no internalization of the receptor antagonist
complex into tumor cells [32]. Receptor antagonists
(e.g.,111In-DOTA-SST-ANT) with receptor affinity compa-
rable to that of SSTR agonists readily bind SSTR-expressing
tumors to a higher extent than agonists and with a long tumor
retention time, as described in an HEK-SSTR2 tumor-bearing
mouse study [38]. Factors contributing to this phenomenon
include the fact that receptor antagonists occupy more bind-
ing sites and show a lower dissociation rate than agonists [32].
Cescato et al. [33] evaluated the in vitro binding of the
receptor antagonist 177Lu-DOTA-BASS in comparison with
that of 177Lu-DOTATATE in a study of tissue sections of
surgically resected SSTR2-expressing tumor samples. In all
cases, the tumor tissues were more intensely labeled using the
SSTR antagonist, demonstrating that the antagonistic radio-
ligand detected more binding sites in a large variety of dif-
ferent tumor types, including NETs. On average, 4.2-fold
increased binding was found using 177Lu-DOTA-BASS. This
improved binding may increase the sensitivity of imaging
with such receptor antagonist tracers. The first clinical data
published thus far comprise a feasibility study in five patients,
in whom it was confirmed that 111In DOTA-BASS provided a
higher tumor uptake and better visualization of metastatic
NETs than 111In-DTPA-octreotide [34]. Moreover, the kid-
ney retention of the antagonistic compound was lower,
resulting in a 5.2 times higher tumor-to-kidney ratio in favor
of the receptor antagonist. Also the liver radiation dose
appeared to be lower using the receptor antagonists. The
lower renal and liver doses, as seen in preclinical and clinical
studies [32, 34, 39], can be explained by charge differences
between the two compounds.
High tumor uptake, long tumor retention time and less
physiological retention of radioactivity in healthy organs
indicate that SSTR antagonists are very promising not only
for diagnostic, but also for therapeutic purposes. A disad-
vantage of these antagonists is the fact that their tumor uptake
and retention are highly influenced by the choice of chelator
and the radionuclide being used [40]. Therefore, it can be
difficult to predict tumor dosimetry for PRRT using a diag-
nostic SSTR antagonist labeled with another radionuclide.
Since SST is a hormone with a repressive effect on
tumor growth, SSTR antagonists may theoretically exert a
tumor-proliferating effect. However, as yet, there has been
no clinical or preclinical report of increased tumor prolif-
eration after treatment with SSTR antagonists. More clin-
ical trials now need to be performed to confirm the safety
and effectiveness of applications of these peptide analogs.
Application of radionuclide combinations
and a-emitters
90Y and 177Lu are currently the most widely applied ra-
dionuclides for treatment with radiolabeled SST analogs.
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The high-energy electrons (11 mm maximum tissue pene-
tration) emitted by 90Y suggest that this radionuclide will
be more effective in larger tumor masses (optimal diameter
of 34 mm [41]) as smaller tumors will not absorb all the
energy released. Accordingly, the low-energy electrons
emitted by 177Lu (1.8 mm maximum tissue penetration)
make this radionuclide more suitable for treatment of
smaller tumor masses (optimal diameter of 2 mm) [41].
These characteristics suggest that an optimal anti-tumor
response in larger tumor masses as well as in smaller
metastases could be achieved using a combination of both
90Y-DOTATOC and 177Lu-DOTATATE. This was con-
firmed in a preclinical study in rats bearing both smaller
and larger tumors, mimicking the varying size of metas-
tases that can be found within a single patient. The com-
bination of 90Y-DOTATOC and 177Lu-DOTATATE gave
superior results compared with a single dose of either 90Y-
DOTATOC or 177Lu-DOTATATE [42]. Reports of the first
clinical applications of combinations of both 90Y-DOTA-
TOC and 177Lu-DOTATATE were published recently.
Kunikowska et al. [43] performed a study in patients
treated with 90Y-DOTATATE alone or 177Lu-DOTATATE
plus 90Y-DOTATATE (concurrent therapy with 1:1
radioactivity ratio). The combined treatment resulted in
longer overall survival times than were obtained with 90Y-
DOTATATE alone, whereas the safety of both methods
was comparable. Villard et al. [44] retrospectively com-
pared treatment with alternating sequential 177Lu-DOTA-
TOC and 90Y-DOTATOC (DUO-PRRT) in 237 patients
versus 90Y-DOTATOC alone in 249 patients and con-
cluded that their results suggested a longer survival after
DUO-PRRT. A prospective clinical study, with a ran-
domized control group and applying patient-specific
dosimetry calculations is still lacking, however. As dis-
cussed by Savolainen et al. [45], an optimal clinical com-
bination of the two radiopharmaceuticals should be
determined on a patient-specific basis. As will be discussed
later, the kidneys are among the dose-limiting organs and
considering the substantially lower dose rate to the kidneys
of 177Lu compared with 90Y, the biologically effective dose
(BED) to the kidneys should be calculated for the specific
tandem combination being applied.
A most promising recent development has been the
application of a-particle-emitting radionuclides such as
213Bi or its mother radionuclide 225Ac (Figs. 1, 2) in PRRT.
These radionuclides emit particles with a high energy
(8.32 MeV for 213Bi/213Po and 27.5 MeV for 225Ac)
combined with small particle ranges of only 50–80 lm.
The LET is much higher for a particles than for b particles,
which might further enhance the therapeutic efficacy of
PRRT, especially in small tumor lesions including micro-
metastases. Moreover, the cytotoxic effect of a radiation is
independent of the cell cycle phase and oxygen
concentration [46, 47], being beneficial especially for
treatment of less oxygenated, hypoxic tumor regions.
Moreover, the use of a-emitters minimizes the effect of cell
cycle heterogeneity on tumor response to PRRT, whereas
for b-emitters tumor responses do depend on cell cycle
phase [48].
When a-emitters are stably complexed to targeting
peptides and receptor density in normal tissue is relatively
low, radiotoxicity in non-targeted normal tissues can be
expected to be minimal, based on the short path length of a
Fig. 1 Decay of 225Ac; four consecutive a-particle-emitting daugh-
ters are formed during decay (color figure online)
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radiation. This was confirmed in a rat study in which 213Bi-
DOTATOC showed a dose-related tumor anti-proliferative
effect without side effects in normal organs [10]. In a pilot
study in three patients, no short-term adverse side effects
on kidney or bone marrow were found after 213Bi-
DOTATOC, whereas there was a marked reduction in
tumor vascularity and no progression of metastases during
follow up for 9 months in patients with NET refractory to
90Y-DOTATOC or 177Lu-DOTATOC [49].
One of the safety concerns in relation to 225Ac is the
formation of four consecutive daughter radionuclides dur-
ing its decay. Safe application will be challenging, because
the recoil kinetic energy delivered to the daughter nuclides
during 225Ac decay is high, which might result in the
presence of a-emitting daughters free from the targeting
chelator–peptide complex. An accumulation of free a-
emitters such as, for instance, 213Bi in the renal cortex may
cause late nephrotoxicity as was shown at the highest doses
used in mice studies with 225Ac-DOTATOC [47, 50]. A
disadvantage of the use of 213Bi is its half-life of only
46 min and the fact that it is produced from a 225Ac gen-
erator that generates 213Bi for only 10–15 days. Never-
theless, if in phase I and II clinical trials, the use of
a-emitters is shown to be safe, application of these radio-
nuclides or a combination of a- and b-emitters might be a
revolutionary way to target and eradicate tumors in NET
patients.
Intra-arterial administration
Unlimited growth of hepatic metastases resulting in liver
failure is one of the most common causes of death in
patients with gastroenteropancreatic NETs (GEP-NETs).
This is why liver-directed therapies are developed, such as
hepatic embolization of the liver metastases and debulking
hepatectomy when indicated. In line with this approach,
several research groups have examined whether local i.a.
administration might, compared with systemic i.v. admin-
istration, increase uptake of radionuclides in hepatic
metastases [51, 52]. Since hepatic metastases depend
mainly on the hepatic artery for their supply of oxygen and
nutrients, the higher arterial radiopeptide uptake during the
first pass through the liver after i.a. administration was
expected to lead to superior tumor uptake and better
options for treatment of patients with a high metastatic
liver load [52]. In a preclinical rat liver metastasis model,
Pool et al. [53] demonstrated 111In-DTPA-octreotide tumor
uptake to be twice as high after loco-regional administra-
tion via the hepatic artery than after i.v. administration.
Furthermore, in a patient study, increased uptake of ra-
dionuclides in liver metastases has been reported after i.a.
administration [54]. Kratochwil et al. [54] compared stan-
dard uptake values (SUVs) after i.a. administration of
68Ga-DOTATOC versus i.v. administration in 15 NET
patients; SUVs were 3.75-fold higher after i.a. adminis-
tration [54]. The same group [52] performed a pilot study
in which 90Y- or 177Lu-DOTATOC was infused via the
hepatic artery in 15 patients with liver metastases arising
from GEP-NETs. This resulted in a higher rate of objective
radiological responses than typically reported for the i.v.
regime, i.e., 60 vs. 30 %, respectively. However, the
promising observations of locally administered and b-par-
ticle-based PRRT need to be confirmed in a larger number
of patients and compared with a proper control group
treated intravenously.
In addition to the favorable higher uptake of radiola-
beled SST analogs after i.a. administration, a locally higher
serum concentration of the radiopeptide increases the risk
of (partial) receptor saturation. Kratochwil et al. [52], using
dynamic imaging, assessed pharmacokinetic data after i.a.
and i.v. infusion of 111In-DOTATOC (250 MBq/150 lg)
within the same patients (n = 4). They found i.a. admin-
istration to result in a 3.5-fold increased uptake in the
initial phase, which decreased after 10 min, and according
to the authors this was due to saturation effects. This
Fig. 2 Planar posterior image
of the liver 24 h after i.v. and
24 h after i.a. administration of
111In-octreotide. LK left kidney,
RK right kidney, S spleen,
L liver, LM three liver
metastases visible after i.a.
injection. After i.a.
administration, there was
increased tumor uptake of 111In-
octreotide
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indeed indicated that maximum achievable tumor uptake
might be limited by receptor saturation. Therefore, a higher
specific activity, which means an increased amount of
radioactivity labeled to the same amount of SST analog,
might be pivotal for this kind of therapy. Increased specific
activity, either by optimization of the radiolabeling pro-
cedure or by labeling of the peptide with non-carrier-added
177Lu, might therefore allow enhanced levels of radionuc-
lides within liver metastases after i.a. administration.
Even though i.a. administration is far more complex
than i.v. administration, it has nevertheless been reported to
be a safe procedure [54]. Therefore, considering the results
achieved in pilot experiments, a randomized clinical trial
comparing responses to PRRT after i.a. administration
versus responses after i.v. administration in NET patients
with a high hepatic tumor load would be of great interest,
allowing a clear evaluation of the potential treatment
benefits achieved after i.a. administration.
Tumor dosimetry and organs at risk
Organs at risk
Severe permanent renal toxicity (grade 4) has been
observed to occur late (1–10 years) after the start of PRRT
treatment with 90Y-DOTA-octreotide in 102 out of 1,109
(9 %) patients after a fixed activity of 3.7 GBq/m2 body
surface area [55]. Severe hematological toxicity (grade
3–4) occurred in 13 % of the patients, mostly transient but
in a few cases (3 out of 1,109) developing into myelo-
dysplastic syndrome (MDS) or leukemia [44]. Hemato-
logical toxicity of equivalent severity (grade 3 or 4) was
also reported in 10 % of 504 patients treated with 177Lu-
DOTA-octreotate according to a fixed dosing scheme of
4 9 7.4 GBq, again with some (3 out of 504) developing
into MDS 2–3 years after the last treatment [29]. The same
level of hematological toxicity was reported by Sabet [56]:
23/203 (11 %) developed grade 3 and 4 hematological
toxicity and three patients (1.4 %) developed MDS. Radi-
ation-induced renal insufficiency has not been reported in
any study of therapy with 177Lu-DOTA-octreotate alone.
Kidney dosimetry
Physiological uptake of peptides in the kidneys is con-
centrated at the proximal tubuli distributed over the cortex
where reabsorption of proteins from the primary urine back
into the blood stream takes place. This uptake can be
partially blocked by giving patients a co-infusion of amino
acids, which results in 35 % reduction of renal uptake in
PRRT performed in clinical practice [57]. Retrospective
analysis of cases of late-occurring renal toxicity with 90Y-
DOTA-octreotide showed that the absorbed dose is a pre-
dictor of renal toxicity [58]. Accurate dosimetry is needed,
which accounts for both the individual kidney kinetics and
the actual kidney volume irradiated. The absorbed dose to
the kidneys per therapy cycle is also an important risk
factor; a higher dose rate and a higher dose per fraction
lead to more renal damage, as expressed by the BED,
calculated according to the linear quadratic (LQ) model:
BED ¼ D 1þ Tl
Tl þ Teff 
d
a=b
 !
where Tl is the repair half-life of repairable damage, Teff
the effective half-life of the kidney dose buildup, a/b the
radiation sensitivity parameter, d the absorbed dose per
therapy cycle, and D the total absorbed dose. The dose
threshold for renal damage after external beam radiation
given in 2 Gy fractions is 20–23 Gy, whereas after 90Y-
DOTA-octreotide a 5–8 Gy higher threshold was observed,
which could be well explained by the LQ model-based
BED [59].
Renal toxicity by radiation exposure develops slowly
after the initial tubular radiation damage. Besides the BED,
additional risk factors are older age, diabetes, hypertension
and use of nephrotoxic drugs prior to PRRT [60, 61]. From
these findings, two absorbed dose thresholds are now being
postulated: a BED of 40 Gy for patients without risk fac-
tors and a BED of 28 Gy for patients with multiple risk
factors for renal problems [61]. Patients with risk factors
also tend to show a higher dose to the kidneys per
administered activity compared with patients without risk
factors, although more patients than the 28 patients
(including 11 with risk factors) studied by Guerriero et al.
[62] are needed for significance.
Tailoring personalized PRRT to the absorbed dose limit
requires dosimetric methods of the highest accuracy. The
inter-patient variability in kidney dosimetry is too great to
justify the use of a group-averaged absorbed dose, as is
customary with diagnostic radiopharmaceuticals. The
BED-based limits derived for 90Y-DOTA-octreotide ther-
apy are assumed to be valid also for 177Lu-DOTA-octreo-
tate, although no renal toxicity has been observed for this
therapy. In a phase I trial with 90Y-DOTA-octreotide, a
pure b-emitter, dosimetry was based on pre-therapeutic
imaging with the PET analog 86Y-DOTA-octreotide [63].
This method resulted in proof of a correlation between
BED and renal toxicity [58]. Kidney dosimetry for c-
emitters is traditionally based on planar imaging with
activity quantification by the conjugate view method. In a
comparison between conjugate view and quantitative
SPECT imaging of the kidney uptake of 177Lu-DOTA-
octreotate, the planar method resulted in an overestimation
of the absorbed dose together with a high variance in
60 Clin Transl Imaging (2014) 2:55–66
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background, both due to overlapping radioactivity [64].
Post-therapeutic planar imaging after PRRT with co-
administration of 111In-DOTA-octreotide did, however,
yield supporting evidence for the toxicity threshold to be
used in PRRT with 90Y-DOTA-octreotide [59, 61].
In a dosimetry study in which 200 patients were treated
with 177Lu-DOTA-octreotide the absorbed dose ranged
between 2 and 10 Gy (median 4.5 Gy) per therapy cycle,
corresponding to a BED range of 2–16 Gy (median
4.9 Gy) [65].
The difference in renal toxicity incidence after 90Y-
DOTA-octreotide versus 177Lu-DOTA-octreotate at almost
equivalent kidney doses seems to be evident. The radiation
exposure by 90Y will be more homogeneous than by 177Lu,
because of the longer tissue penetration range of the par-
ticles emitted by 90Y in comparison to the shorter range of
those emitted by 177Lu. The activity distribution of the
peptide in the kidney is not homogeneous as was shown in
ex vivo autoradiographs of excised kidney sections from
patients injected with 111In-DTPA-octreotide prior to
nephrectomy [66]. The radioactivity was mostly confined
to the cortex with a streaky pattern gradient from high
concentration in the outer part to low concentration in the
medulla [67]. Yttrium-90 resulted in a much more homo-
geneous dose distribution than 177Lu [78]. The absorbed
dose distribution in the kidneys has also been calculated on
SPECT/CT with 111In-DTPA-octreotide [68]. Uptake in the
cortex and fall-off of the absorbed dose at the boundaries
already introduce inhomogeneities in the dose distribution,
although not as extreme as for ex vivo autoradiography-
based 177Lu dose distribution. In the absence of clear dose-
related renal toxicity, the exact dose limit for 177Lu-
DOTA-octreotate is still unclear, and the sparing effect of
the inhomogeneous dose distribution is also speculative.
Bone marrow dosimetry
The absorbed dose to the bone marrow is not always rou-
tinely determined, as it involves regular blood sampling
and determination of the whole-body distribution. The
blood-based method is used for b-particle bone marrow
dosimetry, given that, for peptides, the bone marrow
radioactivity concentration is equivalent to the concentra-
tion in blood [69, 70]. The c radiation from 177Lu gives an
additional cross-dose from the total body and from organs
and tumors with radioactivity uptake, which can form more
than 60 % of the total bone marrow dose, but it also shows
high variability [69]. The cumulative limit in absorbed
bone marrow dose is considered to be 2 Gy, in line with the
limits used for 131I thyroid cancer therapy [71] to prevent
direct unrecoverable hematological toxicity. The proba-
bility for inducing leukemia and MDS, however, shows a
linear relation with absorbed dose and it is unclear whether
a dose limit would help to keep this risk within reasonable
limits.
With standardized dosimetry methods no clear rela-
tionship has been reported between hematological toxicity
and absorbed bone marrow dose [69, 72]. An almost linear
relation is obtained between dose and reduction of platelet
counts at nadir after 90Y-DOTA-octreotide therapy [69,
72]. The bone marrow dose needs to be corrected by a
weight function aggravating the effects in patients with low
baseline platelet counts without prior chemotherapy and
normal recovery.
Tumor dosimetry
The target for PRRT is metastasized disease including
smaller and microscopic lesions, but it is difficult to deter-
mine the absorbed dose in lesions smaller than 1 cm in size.
The absorbed dose needed for local control of pancreatic
NETs with adjuvant external beam radiotherapy is in the
order of 50 Gy [73]. With PRRT, the median absorbed dose
to obtain a volume reduction of NETs by 90Y-DOTA-
octreotide is 232 Gy [74]. The difference in doses can be
partly explained by the difference in target size (tumor bed
with minimal disease vs tumors ranging between 2 and
500 g) and the differences in dose rate and uniformity.
The absorbed dose to the tumor shows huge inter-patient
variance. Liver metastases were reported to receive a dose
of 167 ± 139 Gy for the first treatment cycle with 7.4 GBq
[75]. Responders showed a [20 % decrease in absorbed
dose in the following treatment cycles. Variance in the
tumor dose and its reduction with each subsequent therapy
cycle were also reported by Garkavij et al. [64]; the median
absorbed dose to the tumor in their study of 177Lu-DOTA-
octreotate-treated patient was reported to be 207 Gy (range
17–387 Gy).
Treatment planning for PRRT
Hardly any centers follow a dosimetry-guided administra-
tion scheme for PRRT. Most PRRT therapies are given
according to a fixed activity administration scheme. With
90Y-DOTA-octreotide the administered activity is scaled
by the patient’s body surface area at doses of 3.7 GBq/m2.
This dosing scheme is based on phase I trials with the
compound, indicating a dose-limiting toxicity in the kid-
neys above 7.4 GBq/m2 after a short follow-up of 150 days
and partial absence of kidney protection by amino acid
infusions [76]. Longer follow-up of the patients in other
phase I trials did show the benefit of dosimetry-guided
therapy or, as a second option, of using lower administered
activities per treatment cycle [58, 61, 63]. By lowering the
activity per treatment cycle the total BED to the kidneys
will decrease and thus reduce the risk of renal toxicity.
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For 177Lu-DOTA-octreotate the most commonly used
fixed dosing scheme is based on the protocol used by
Kwekkeboom et al. [29]: four treatment cycles of 7.4 GBq.
Originally some patients were excluded from getting the
fourth treatment cycle, as they would otherwise have
exceeded the conservative kidney dose limit of 23 Gy. This
same limit of 23 Gy is applied in the dosimetry guided
treatment schedule used by Sandstro¨m et al. [65]: the 200
patients in their study were treated by consecutive cycles of
7.4 GBq, until the 23 Gy limit was reached; 50 % of the
patients received more than four cycles, with cycles
received ranging between 2 and 10.
A treatment schedule based on dosimetry should focus
on the absorbed dose both to the kidneys and to the bone
marrow. Volume delineation of the renal cortex is not a
straightforward procedure and it is time consuming when
done manually. The exact volume is not needed when
using average activity concentrations over a volume inside
a representative sample of the kidney [65]. The quantitative
SPECT method uses this same principle, but also trans-
forms the activity concentration to an SUV by considering
the total body uptake measured at 40-60 min after the
177Lu therapeutic dose before any voiding [77]. This same
method is also used for determining the absorbed dose in a
section of the patient’s spine as a representative sample for
the bone marrow.
Patients who are retreated with two additional cycles of
177Lu-DOTA-octreotate PRRT after relapse following the
first treatment do not show renal toxicity [78, 79]. Con-
sidering the variance observed in kidney dosimetry, a
cumulative activity of 44 GBq could lead to a kidney BED
of between 11 and 90 Gy, according to the range reported
in 200 patients by Sandstro¨m et al. [65].
Combination of PRRT with other treatments
Interesting combination options include PRRT as an
adjuvant treatment after surgery, as this approach might
prevent development of tumor lesions after spread of
tumor cells during surgery, or eradicate micro-metastases
that had already developed prior to surgery. This PRRT
approach was studied in a preclinical model, mimicking
perioperative tumor spill by injection of SSTR-positive
tumor cells into the portal vein. In this study, 177Lu-
DOTATATE treatments significantly reduced or pre-
vented tumor development [80]. PRRT can also be
applied as a neo-adjuvant treatment to achieve tumor size
reduction and thus allow curative surgery. This was suc-
cessfully performed recently in two patients with pan-
creatic NETs [81, 82].
Another option to improve anti-tumor response is to
combine PRRT with chemotherapeutics; the latter may be
applied to obtain radiosensitization of the tumor cells
through modulation of cellular and molecular interactions
causing, for example, enhanced DNA damage and repair,
cell-cycle synchronization, apoptosis, tumor cell re-oxy-
genation or inhibition of cell proliferation. Radiosensitizing
agents are commonly used in combination with external
beam radiation therapy. Drugs with radiosensitizing effects
based on cellular and molecular interactions include cam-
ptothecin, gemcitabine, and 5-fluorouracil (5-FU) or its
prodrug capecitabine (Cap). The radiosensitizing effect of
camptothecin is due to its ability to prevent DNA relega-
tion by binding to topoisomerase I, which inhibits repair of
single stranded breaks caused by radiation. Gemcitabine
causes accumulation of tumor cells in the radiosensitive
G2/M phase, making the tumor cells more sensitive to
PRRT. Cap not only abrogates DNA replication through
insertion of chain-stopping nuclides, it is also a thymidine
synthetase inhibitor causing depletion of thymidine.
Besides its radiosensitizing effects, Cap has also been
described to deplete the tumor cell’s methylguanine DNA
methyl transferase, an enzyme responsible for the repair of
DNA damage caused by the DNA alkylating agent tem-
ozolomide (TMZ) [50]. In their clinical study, Claringbold
et al. [83] used a treatment scheme based on these findings.
This scheme consisted of 14 days of Cap treatment, start-
ing 5 days before radiopeptide administration, and the
administration of TMZ during the last 5 days of Cap
treatment [83].
Until now the radiosensitizing effects as described
above have been the main focus for clinical application of
combinations of PRRT with chemotherapeutics [83–86].
Some challenges have to be faced during such studies
though. Indeed, tumor uptake of radionuclides during
PRRT depends on both tumor vascularization and SSTR
expression, both of which can be affected by anticancer
therapeutics [87–89].
In our preclinical study in mice, an increased tumor
perfusion was measured for 14 days after TMZ treatment.
This resulted in an increased uptake of radiopeptide after
TMZ treatment [89].
Considering SSTR expression, Fueger et al. [87]
examined the possible influence of cytotoxic or cytostatic
agents on binding characteristics of an SST ligand
in vitro. They found a reduced expression of high-affinity
DOTA-LAN binding sites in response to incubation with
gemcitabine, camptotecin, mitomycin C and doxorubicin
(Table 1). In the case of gemcitabine, a four-day recovery
eventually resulted in a significant up-regulation of SSTR.
This was confirmed in a study by Nayak et al. [90], in
which uptake of 177Lu-DOTATOC in cells in culture was
1.5–3 times increased 4 days after gemcitabine exposure
compared with that in untreated control cells. Besides
SSTR up-regulation the treated cells also showed cell cycle
62 Clin Transl Imaging (2014) 2:55–66
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modulation; most of the viable cells were in the radiosen-
sitive G2/M phase. These effects resulted in a synergistic
effect of gemcitabine and 177Lu-DOTATOC [90].
As RAD001 or everolimus has been shown to be
effective against pancreatic NETs [91], a combination of
PRRT with RAD001 could be another promising PRRT
combination therapy option. In a preclinical study, how-
ever, the combination of RAD001 and PRRT was less
effective compared with PRRT alone [68]. As RAD001 has
been shown to cause a G1 arrest [92], Pool et al. [93]
suggested this as a possible explanation for the reduced
tumor response to the combination of mTOR-inhibitor
everolimus (RAD001) with 177Lu-DOTATATE. Because
NET cells have a peak of radio-resistance during the early
G1 phase [48], the tumor cells may have been less sensitive
to 177Lu-DOTATATE when administered after the start of
RAD001 treatment.
As regards the clinical application of PRRT in com-
bination with other anticancer agents, to date only phase
II clinical trials have been reported. In these studies,
PRRT using 177Lu-DOTATATE was combined with
5-FU or Cap, supplemented or not supplemented with
TMZ. 5-FU combined with high-dose 111In-octreotide
appeared to be safe in a study of 21 patients, but did
not add to therapeutic response rates compared with
111In-octreotide alone [94]. Administration of 5-FU or
Cap ? PRRT was reported to be safe in the studies of
Barber et al. [84] and van Essen et al. [85]. These
authors decided to continue this study with a two-armed,
randomized, prospective study to compare the combina-
tion of 177Lu-DOTATATE with Cap versus 177Lu-
DOTATATE alone. Claringbold et al. [83, 86] concluded
that both Cap and the combination of Cap and TMZ
could be safely combined with PRRT. After their study
combining Cap and TMZ with PRRT in 35 patients, the
authors reported that response rates and progression-free
survival times appeared to exceed results with 177Lu-
DOTATATE as a single agent [83]. In their study, GEP-
NETs showed better responses than enteric NETs.
Therefore, the overall response rate seen in GEP-NETs
almost certainly reflected the synergistic effect of TMZ,
whereas the partial responses seen in enteric NET
patients were attributable to the radiopeptide component
of the multimodality therapy. This suggests that the
optimal combination of PRRT and chemotherapy should
be selected for each NET subtype.
Table 1 Combination of PRRT with other therapeutic agents
Therapeutic agent Mechanism of action Studies Results References
Gemcitabine Chain stopper and ribonuclease reductase
inhibitor
Chromosome aberration
Cell cycle synchronization
In vitro
study
SSTR expression was downregulated
during exposure, then restored and
upregulated 4 days after exposure,
resulting in synergism with 177Lu-
DOTATATE
[87, 90]
Camptothecin Binds to topoisomerase I and DNA complex,
preventing DNA relegation
Enhanced apoptosis
Cell cycle arrest
In vitro
study
SSTR expression was downregulated
during camptothecin exposure
[87]
Mitomycin C Cross-linking DNA In vitro
study
SSTR expression was downregulated
during mitomycin C exposure
[87]
Cisplatin Crosslinking DNA
Repair inhibition
In vivo
study
Cisplatin ? 177Lu-DOTATOC was
23 % more effective than 177Lu-
DOTATOC alone
[87]
Doxorubicin Intercalating with DNA
Cell cycle arrest
In vivo
study
Doxorubicin ? 177Lu-DOTATOC
was 14 % more effective than 177Lu-
DOTATOC alone
[87]
RAD001 (everolimus) mTOR inhibitor
Cell cycle arrest
In vivo
study
RAD001 ? 177Lu-DOTATATE was
less effective than 177Lu-
DOTATATE alone
[93]
5-fluorouracil or its prodrug
capecitabine
Chain stopper and thymidine synthetase
inhibitor
Repair inhibition
Cell cycle arrest
Phase II
clinical
trial
Combination with 177Lu-DOTATATE
appeared to be safe
[84–86]
Temozolomide DNA alkylating agent Phase II
clinical
trial
Combination with capecitabine
and177Lu-DOTATATE appeared to
be safe
[83]
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Concluding remarks
Even though PRRT is a most promising therapy for NET
patients in whom curative surgery is no longer an option,
there is still room for improvement as discussed in this
review.
The increased tumor uptake of radionuclides reported in
the case of radiolabeled SSTR antagonists or i.a. admin-
istration is promising. More clinical studies are now needed
to establish the value of these approaches.
As regards the combined use of 90Y and 177Lu, there is a
clear need for comparative studies before the effectiveness
of this combination can be evaluated. Alpha-emitters have
promising features; the first studies have just been per-
formed and longer follow-up periods are now needed to
investigate potential long-term toxicity.
With regard to individual dosimetry, a large percentage
of patients might receive additional treatment cycles before
reaching dose-limiting toxicity levels as has been deter-
mined in kidneys and bone marrow. However, whether or
not additional cycles will have a major influence on tumor
response is not yet known.
Combinations of PRRT with other anticancer therapies
have appeared to be safe, but to date only phase II clinical
trials have been reported. In addition, only a small number
of anticancer agents have been combined with PRRT,
leaving numerous possible options for further research.
In conclusion, several directions to improve PRRT
effects have been indicated, but additional preclinical and
especially translational and clinical research are needed to
obtain further proof of value.
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